Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ascendis Pharma A (ASND) over the last 10 years, with Q3 2025 value amounting to $91.9 million.

  • Ascendis Pharma A's Accounts Payables rose 1116.38% to $91.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.9 million, marking a year-over-year increase of 1116.38%. This contributed to the annual value of $104.3 million for FY2024, which is 253.92% up from last year.
  • Per Ascendis Pharma A's latest filing, its Accounts Payables stood at $91.9 million for Q3 2025, which was up 1116.38% from $106.1 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Accounts Payables peaked at $141.1 million during Q1 2023, and registered a low of $53.2 million during Q2 2021.
  • Moreover, its 5-year median value for Accounts Payables was $91.9 million (2025), whereas its average is $95.6 million.
  • Per our database at Business Quant, Ascendis Pharma A's Accounts Payables soared by 16035.1% in 2021 and then crashed by 3752.98% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Accounts Payables (Quarter) stood at $68.0 million in 2021, then skyrocketed by 51.65% to $103.1 million in 2022, then dropped by 1.29% to $101.7 million in 2023, then grew by 1.24% to $103.0 million in 2024, then dropped by 10.79% to $91.9 million in 2025.
  • Its Accounts Payables stands at $91.9 million for Q3 2025, versus $106.1 million for Q2 2025 and $88.7 million for Q1 2025.